RxDoctor Payments DataLook up a doctor →

Lawrence Woodard, MD

Ophthalmology · Atlanta, GANPI 1790713931

Payments from drug & device makers

$577,788in general payments, 2019–2025

Across 638 payments — averaging $905.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$424K
  • Alcon Research LLC$124K
  • Sight Sciences, Inc.$21K
  • Glaukos Corporation$3K
  • Tarsus Pharmaceuticals, Inc.$2K
  • Ivantis, Inc$2K
  • plus $3K from 18 others

What the payments were for

  • Consulting fees$382,49066%
  • Speaking & faculty fees$144,85025%
  • Grants$7500%
  • Travel & lodging$29,4825%
  • Food & beverage$17,5693%
  • Education$360%
  • Gifts$2,5640%
  • Entertainment$470%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$577,788 in reported general payments places this provider in the 95th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$542,909
Medicare patients
626
Services billed
2,445

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProlensaBromfenac Sodium209$75,775
LumiganBimatoprost30$15,979
Bromfenac Sodium68$13,402
VyzultaLatanoprostene Bunod19$5,891
Prednisolone Acetate106$3,346
Brimonidine Tartrate14$1,712
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat54$979
Timolol Maleate87$942
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol12$931
Latanoprost51$552
Ketorolac Tromethamine25$477
Tobramycin41$179
Ofloxacin19$175

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$56$75,775209 claims
AbbVieLumigan$89$15,97930 claims
Bausch & Lomb Americas Inc.Vyzulta$85$5,89119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →